Back to Search
Start Over
Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
- Source :
- BMC Gastroenterology
- Publisher :
- Springer Nature
-
Abstract
- Background Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in patients who maintain undetectable serum hepatitis B virus (HBV) DNA after initial entecavir treatment. Methods In this open-label trial, patients who had serum HBsAg and HBV DNA levels ≥1,000 IU/mL and 0.5 log10 IU/mL. Eleven patients (23.4%) in the telbivudine group, but none in the entecavir group, experienced virologic breakthrough (P
- Subjects :
- Male
0301 basic medicine
Hepatitis B virus
medicine.medical_specialty
HBsAg
Guanine
Resistance
Virologic response
medicine.disease_cause
Antiviral Agents
03 medical and health sciences
0302 clinical medicine
Pegylated interferon
Internal medicine
Telbivudine
Drug Resistance, Viral
medicine
Humans
Virologic breakthrough
Hepatitis B Surface Antigens
business.industry
Gastroenterology
virus diseases
General Medicine
Entecavir
Middle Aged
Viral Load
Hepatology
Hepatitis B
medicine.disease
Virology
030104 developmental biology
Hepatitis B surface antigen
DNA, Viral
Female
030211 gastroenterology & hepatology
business
Viral load
Thymidine
Research Article
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 1471230X
- Volume :
- 17
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMC Gastroenterology
- Accession number :
- edsair.doi.dedup.....e315edc10176dec53989156da3c94830
- Full Text :
- https://doi.org/10.1186/s12876-017-0572-2